About FOSUN PHARMA Company

Established in 1994, Fosun Pharmaceutical (stock code: 600196.SH, 02196.HK) is an innovation-driven global medical and health industry group rooted in China. It directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services, and covers the pharmaceutical business sector through its participation in Sinopharm Holdings. The Group is patient-centered and guided by clinical needs. Through cooperative models such as independent R&D, cooperative development, license introduction, and deep incubation, the Group continues to enrich the innovative product pipeline, enhance the research and clinical development capabilities of FIC (First-in-Class, or Best-In-Class) products, and accelerate the development and transformation of innovative technologies and products. Under the strategic guidance of “4IN” (Innovation Innovation, Internationalization, Intelligent Intelligentization, Integration), the Group adheres to the development model of “innovative transformation, integrated operation, and steady growth” and the belief of creating value for shareholders, continuously strengthens independent R&D and external cooperation, enriches product pipelines, strengthens global layout, and actively promotes business focus to rapidly improve operational efficiency and assets Efficiency is committed to becoming a first-class enterprise in the global mainstream healthcare market.